Matthew Rettig
0000-0002-7394-3056
4 papers found
Refreshing results…
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
Missing publications? Search for publications with a matching author name.